Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

Blood - Tập 122 Số 6 - Trang 981-987 - 2013
Daryl Tan1, Sandra J. Horning2, Richard T. Hoppe3, Ronald Levy2, Saul A. Rosenberg2, Bronislava M. Sigal4, Roger A. Warnke5, Yasodha Natkunam5, Summer S. Han4, Alan R. Yuen2, Sylvia K. Plevritis4, Ranjana H. Advani2
1Department of Medicine, Oncology Division, Stanford University, Stanford, CA 94305, USA
2Department of Medicine, Oncology Division,
3Department of Radiation Oncology
4Department of Radiology, and,
5Department of Pathology, Stanford University, Stanford, CA

Tóm tắt

Key Points This study is a retrospective analysis of long-term outcomes of patients with FL treated at Stanford University for 4 decades. Study results showed significant improvement in OS in patients with FL despite no change in event-free survival after first-line therapy.

Từ khóa


Tài liệu tham khảo

1997, A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project., Blood, 89, 3909, 10.1182/blood.V89.11.3909

Horning, 1984, The natural history of initially untreated low-grade non-Hodgkin’s lymphomas., N Engl J Med, 311, 1471, 10.1056/NEJM198412063112303

Acker, 1983, Histologic conversion in the non-Hodgkin’s lymphomas., J Clin Oncol, 1, 11, 10.1200/JCO.1983.1.1.11

Garvin, 1983, An autopsy study of histologic progression in non-Hodgkin’s lymphomas. 192 cases from the National Cancer Institute., Cancer, 52, 393, 10.1002/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M

Montoto, 2011, Transformation of indolent B-cell lymphomas., J Clin Oncol, 29, 1827, 10.1200/JCO.2010.32.7577

Tan

Horning, 1993, Natural history of and therapy for the indolent non-Hodgkin’s lymphomas., Semin Oncol, 20, 75

Fisher, 2005, New treatment options have changed the survival of patients with follicular lymphoma., J Clin Oncol, 23, 8447, 10.1200/JCO.2005.03.1674

Swenson, 2005, Improved survival of follicular lymphoma patients in the United States., J Clin Oncol, 23, 5019, 10.1200/JCO.2005.04.503

Liu, 2006, Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center., J Clin Oncol, 24, 1582, 10.1200/JCO.2005.03.3696

Marcus, 2005, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma., Blood, 105, 1417, 10.1182/blood-2004-08-3175

Hiddemann, 2005, Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group., Blood, 106, 3725, 10.1182/blood-2005-01-0016

Salles, 2007, Final Analysis of the GELA-GOELAMS FL2000 Study with a 5-Year Follow-Up., Blood, 110

Herold, 2007, Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study., J Clin Oncol, 25, 1986, 10.1200/JCO.2006.06.4618

Marcus, 2008, Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma., J Clin Oncol, 26, 4579, 10.1200/JCO.2007.13.5376

Hochster, 2009, Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study., J Clin Oncol, 27, 1607, 10.1200/JCO.2008.17.1561

Jaffe

Brice, 1997, Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte., J Clin Oncol, 15, 1110, 10.1200/JCO.1997.15.3.1110

Solal-Céligny, 2004, Follicular lymphoma international prognostic index., Blood, 104, 1258, 10.1182/blood-2003-12-4434

Kaplan, 1958, Nonparametric estimation from incomplete observations., Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452

Peto, 1973, Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data., Biometrics, 29, 579, 10.2307/2529177

Human Mortality Database University of California, Berkeley (USA) and Max Planck Institute for Demographic Research (Germany) Available at: http://www.mortality.org or http://www.humanmortality.de Accessed October 16, 2011

Ederer, 1961, The relative survival rate: a statistical methodology., Natl Cancer Inst Monogr, 6, 101

Voutilainen, 1998, SURV2: Relative Survival Analysis Program, version 3. Vol Version 3

Friedberg, 2009, Follicular lymphoma in the United States: first report of the national LymphoCare study., J Clin Oncol, 27, 1202, 10.1200/JCO.2008.18.1495

Solal-Céligny, 1996, Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d’Etude des Lymphomes de l’Adulte., J Clin Oncol, 14, 514, 10.1200/JCO.1996.14.2.514

McLaughlin, 1996, Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma., J Clin Oncol, 14, 1262, 10.1200/JCO.1996.14.4.1262

Velasquez, 2003, Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501., J Clin Oncol, 21, 1996, 10.1200/JCO.2003.09.047

Hsu, 1997, Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial., Blood, 89, 3129, 10.1182/blood.V89.9.3129

Conconi, 2010, Patterns of survival of follicular lymphomas at a single institution through three decades., Leuk Lymphoma, 51, 1028, 10.3109/10428191003743460

Salles, 2008, Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study., Blood, 112, 4824, 10.1182/blood-2008-04-153189

Bachy, 2010, Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival—A study from the groupe d’etude des lymphomes de l’adulte., J Clin Oncol, 28, 822, 10.1200/JCO.2009.22.7819

Schulz, 2007, Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis., J Natl Cancer Inst, 99, 706, 10.1093/jnci/djk152

Sacchi, 2007, Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients., Cancer, 109, 2077, 10.1002/cncr.22649

Federico, 2000, Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi., Blood, 95, 783

Hasselblom, 2007, The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma - a population-based study., Leuk Lymphoma, 48, 736, 10.1080/10428190601187703

Müller, 2012, The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL., Blood, 119, 3276, 10.1182/blood-2011-09-380949